Navigation Links
BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
Date:2/23/2012

uytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. XIAPEX is currently marketed in nine European and Eurasian markets: Austria, Denmark, Finland, Germany, Norway, Spain, Switzerland, Sweden, and the United Kingdom. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, expected revenue growth, and the assumptions underlying or relating to such statements, are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "plan," "estimate," "likely," "may," "will," "could," "continue," "project," "predict", "goal," the negative or plural of these words, and other similar expressions. Our forward-looking statements are only predictions based on our current expectations and our projections about future events. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the statements made by us and by our partner Auxilium Pharmaceuticals, Inc. ("Auxilium") regarding progress toward achievement
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
3. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
4. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
5. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
6. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
7. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
8. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
9. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
10. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
11. BioSpecifics Technologies Corp. Amends Its Rights Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The Healthcare Analytics Summit 2014 ... Salt Lake City , Sept. 24-25 ... respected healthcare organizations in the U.S. and beyond.  HAS ... industry conference devoted to providing immersive learning experiences on ... of both accountable care initiatives and population health ...
(Date:7/29/2014)... IRVING, Texas , July 29, 2014 /PRNewswire/ ... three new web-based applications with breakthrough interactive features ... and workflows for members of Children,s Hospital Association.  ... under the Novation Optimize Solutions umbrella – Value ... of how Novation helps organizations address the most ...
(Date:7/29/2014)... DIEGO , July 29, 2014   ... Nancy Thornberry to its board of ... franchise head, Diabetes and Endocrinology for Merck & ... strategy and overall pipeline management in diabetes, osteoporosis, ... initiated and co-led the program that resulted in ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Research, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- ... that,(1) demonstrate that Azixa(TM) (MPC-6827) is effective in ... (2) reveal a,mechanism by which MPC-6827 exerts its ... by cellular proteins known to be involved,in cancer ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... improvement measures in eight of the 10 hospitals in ... have found a way to reduce kidney injury in ... 7-15 percent of these patients who undergo a coronary ... which can result in death or rapid decline in ... a study published in the July issue of ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... Avenidas is always looking for ways to ... non-profit agency is doing just that with the Third Annual ... event gives seniors the opportunity to learn about how they ... a variety of fun activities, including a Tai Chi demonstration, ... In addition, there will be food tastings, courtesy of Lyfe ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... - Researchers from the Boston University School of Medicine ... a $3.5 million grant from the National Institute on ... treat, and retain" paradigm in Eastern Europe among HIV-infected ... narcology (addiction) care. The project will be known as ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... Mozes HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... people to develop cancer, new British research says. Among ... leukemia or melanoma appears to go up about 16 percent ... "Taller women in our study had increased risk of a ...
... , THURSDAY, July 21 (HealthDay News) -- A new U.S. ... to use the Internet for medical information, and whites are ... the findings released Thursday by the U.S. National Center for ... as likely as Hispanics to search for health information online. ...
... National Nanotechnology Initiative,s (NNI) released four reports that ... focusing on various issues in the nanotechnology environmental, ... series was a part of an ongoing strategy ... from industry, academia, and the Federal Government to ...
... the first time created a way of measuring how much force ... advance is expected to have significant implications for legal forensics. ... the force applied during a stabbing and come up with the ... work has been published in the International Journal of Legal ...
Cached Medicine News:Health News:BUSM/BMC researchers awarded $3.5 million grant from the NIDA 2Health News:Minority participants crucial to effective aging studies 2Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Women, Whites Most Likely to Seek Health Info Online: Survey 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 3
... offers the ease and comfort you've come to ... users in clinical trials agreed that the BD ... depth settings allow you to choose the best ... of lancets, the device also helps eliminate the ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
... The StaRRsed Compact is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: